LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

Search

Actinium Pharmaceuticals Inc

Отворен

1.48 -1.99

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.43

Максимум

1.53

Ключови измерители

By Trading Economics

Приходи

-9.3M

-16M

EPS

-0.51

Служители

31

EBITDA

-9.3M

-17M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+302.68% upside

Дивиденти

By Dow Jones

Следващи печалби

1.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

12M

61M

Предишно отваряне

3.47

Предишно затваряне

1.48

Actinium Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.06.2025 г., 22:33 ч. UTC

Придобивния, сливания и поглъщания

KKR to Acquire Australian Power Provider Zenith Energy

16.06.2025 г., 21:55 ч. UTC

Значими двигатели на пазара

Geospace Technologies Shares Up on Petrobras Pact

16.06.2025 г., 17:04 ч. UTC

Значими двигатели на пазара

Roku Shares Climb on Advertising Deal with Amazon

16.06.2025 г., 23:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.06.2025 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16.06.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16.06.2025 г., 23:10 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16.06.2025 г., 23:02 ч. UTC

Пазарно говорене

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16.06.2025 г., 22:32 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16.06.2025 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16.06.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16.06.2025 г., 21:56 ч. UTC

Печалби

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16.06.2025 г., 21:10 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

16.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.06.2025 г., 20:49 ч. UTC

Пазарно говорене

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16.06.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16.06.2025 г., 20:13 ч. UTC

Пазарно говорене

Natural Gas Gains on Warmer Outlook -- Market Talk

16.06.2025 г., 19:58 ч. UTC

Придобивния, сливания и поглъщания

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16.06.2025 г., 19:13 ч. UTC

Пазарно говорене

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16.06.2025 г., 19:09 ч. UTC

Пазарно говорене

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16.06.2025 г., 18:43 ч. UTC

Пазарно говорене

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16.06.2025 г., 18:36 ч. UTC

Пазарно говорене

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Shopify Appears More Resilient Than Feared -- Market Talk

16.06.2025 г., 18:22 ч. UTC

Пазарно говорене

Citi Forecasts Downturn in Gold Futures -- Market Talk

16.06.2025 г., 16:42 ч. UTC

Пазарно говорене

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16.06.2025 г., 16:37 ч. UTC

Пазарно говорене

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Actinium Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

302.68% нагоре

12-месечна прогноза

Среден 6 USD  302.68%

Висок 9 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Actinium Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.